Artrya Secures Third U.S. Customer as Cone Health Adopts Salix AI Cardiac Platform

Artrya Limited ( (AU:AYA) ) has provided an update.

Artrya Limited has signed a five-year commercial software-as-a-service agreement with Cone Health, a major not-for-profit health system in North Carolina, marking the company’s third U.S. commercial customer for its Salix AI platform. Under the deal, Cone Health will deploy the Salix Coronary Anatomy module on a subscription basis across its network of hospitals and cardiology practices, with additional per-scan revenue for use of the Salix Coronary Plaque module, which is eligible for U.S. reimbursement, while onboarding and ongoing support will be handled by Artrya’s U.S.-based Customer Success team in Atlanta. The agreement, valued at a minimum of US$0.45 million over five years, completes the conversion of all three of Artrya’s U.S. foundation partners into paying customers in 2025, underscoring growing commercial momentum ahead of 2026 and strengthening the company’s foothold in the competitive U.S. cardiac imaging and diagnostics market.

The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.

More about Artrya Limited

Artrya Limited (ASX: AYA) is an Australian medical technology company that develops AI-powered software to improve the detection and management of coronary artery disease. Its proprietary Salix platform analyses coronary CT scans to identify key biomarkers of heart disease, providing near real-time, point-of-care support for clinicians and targeting major cardiac care markets internationally, including the United States.

Average Trading Volume: 920,088

Technical Sentiment Signal: Hold

Current Market Cap: A$626M

See more data about AYA stock on TipRanks’ Stock Analysis page.